Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well my small stake I kept just got smaller.
That's the way I see it to. EOM
The poster is there for all to see what you point out. Expecting
better results ahead with new trail designs that will fully flesh this out.
In reviewing this PR again the questions begs just how good the results can be demonstrated with this new knowledge to design the trails being established.
-- SUNRISE Data Analysis Demonstrates Statistically Significant Overall Survival (OS) Improvement in Patients Receiving Bavituximab plus Docetaxel and Subsequent Immunotherapy Compared to Placebo plus Docetaxel and Subsequent Immunotherapy --
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies, and advancing its proprietary R&D pipeline, today announced the presentation of results of a new analysis of the Phase III SUNRISE trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). Data demonstrated that for patients in the study's bavituximab plus docetaxel treatment arm who received subsequent immunotherapy, the median overall survival (mOS) was not reached, while mOS was 13.0 months for patients in the study's placebo plus docetaxel arm who received subsequent immunotherapy [HR = 0.43; p=0.005]. These are the first clinical results reported supporting the hypothesis that bavituximab may modulate the tumor microenvironment to enhance the anti-tumor activity of immunotherapy agents. Data were presented by Peregrine scientists at the 2017 Annual Meeting of the American Association for Cancer Research (AACR), which is being held April 1-5, 2017 in Washington, D.C.
The presentation highlighted an analysis in which the company evaluated the impact of subsequent immunotherapy treatment, as well as patients' pre-treatment interferon gamma (IFN-γ) levels on overall survival. Overall, low peripheral IFN-γ correlated with more favorable OS in the patients receiving bavituximab + docetaxel and is a biomarker of interest. Data were also analyzed by low versus high IFN-γ levels. For patients with low pre-treatment IFN-γ levels who received subsequent immunotherapy, those in the bavituximab plus docetaxel arm did not reach mOS compared to mOS of 12.1 months for the placebo plus docetaxel arm [HR = 0.24; p < 0.001].
Needs to be repeated.....
Data demonstrated that for patients in the study's bavituximab plus docetaxel treatment arm who received subsequent immunotherapy, the median overall survival (mOS) was not reached
Still got some chips on the table for this one just encase.
Questions soon to be answered I would think.EOM
Thanks MH on your thoughts because this PR to me was a little confusing on first read on looking for the silver lining.
Unusual to be sure EOM
Happy Birthday is in order. Cheers with many more to come in health and safety!
Fingers crossed on both hands.EOM
Makes since to keep a small stake in it just encase.
Can you imagine a partnership PR with the shares available.
The table is set. Talks on partnership very feasible. Nice to own shares when and if the news should break.
Enjoyed this read good perspective. EOM
That is a well thought out statement. EOM
I had several orders in @.75-78 non filled so they held up pretty good.
MH good read very plausible.
News of using the shelf registration showing up in AH I gather.
Not much time to pull the rabbit out of the hat with a major event
to move SP
BKT On April 10TH PP will receive a 7 day notice from from SEC for removal from the listing due to non compliance with minimum bid. Option process left-PP will appeal with panel for another extension with the proviso that the RS remain in tact and used if compliance not attained. Appeal process can take up to 45 days. If Appeal approved an extension will be granted for another 180 days. Probability of approval in my IMO very good.
I believe this is the process as I understand it.
In the CC PP stated this was their plan to SH
nice push
I bought back in myself due to possible extended time being granted for RS.
Good information progress in right direction.EOM
wait and see over for now unloaded
MH Excellent synopsis Thanks
bought a boat load more. see what happens
I sold mine around 8.46 I believe. To think I acquired shares around .35-50 back then if you are referring to TCLN that is.
IMO Investors (me) that trade in and out of their investments are necessarily no less passionate about their believe in a given science then the investor who buys and holds staunchly. Making a profit either way does not diminish ones motivations for acquiring shares to begin with.
If Ronin continues to purchase shares coupled with a decent Q report
we could reach the dollar level and perhaps sustain and grow PPS from there. Either-way he maintains his percentage of ownership and intentionally or otherwise moves the PPS up. PPHM is projected to be profitable in due time so Ronin is the drivers seat.
Filed SC 13D/A on 3/10 added another 3,494,166 something is up!
Got some good orders in this morning so will see where we go from here. GLTA
Let's not confuse a single trade as a brilliant trading strategy of a masterful trader if you were referring in any way to my earlier post. I traded out of my POS and got little braggadocios and chalked up the numbers. However your post was good.
You traded for an assured profit and you can always get back in.
For me 100K @.30-32 out at .62-65 works every time.
Will monitor for another buy in opportunity. GLTU
holding shares is challenging unless your entry point was around .30 cents. Made since to sell. Waiting on another buying point.
Going to monitor developments and hold on picking up anymore shares.
No not all just picking up some profit. How about you?
Yes just unloaded a bunch I bought in .30 range to take some profits. Add more later.
Ok seen enough of this pattern unloaded the rest of my shares while I still see green on my screen. Smaller profit but I can live with it. Now wait on next entry point. I do not know how you LONG LONGS do it. Got to be agonizing somewhat. Best of luck you all deserve it.